Optimizing second-line therapy for chronic myeloid leukemia.
Indian J Cancer
;
2012 Jan-Mar; 49(1): 46-56
Article
Dans Anglais
| IMSEAR
| ID: sea-144551
ABSTRACT
Treatment of chronic myeloid leukemia has evolved from symptom control to long-term disease-free survival with cure potentially round the corner. This required faster, deeper, and longer response. Optimizing treatment decisions therefore requires clear understanding of and strict implementation of guidelines for shift from imatinib. In patients who are resistant to or intolerant of imatinib, second-line TKIs have to be selected carefully. Currently available data show comparable efficacy between nilotinib and dasatinib. With a better safety profile (especially with respect to grade 3 or 4 hematologic toxicity and clinically relevant non-hematologic toxicities), nilotinib becomes the preferred choice in most instances.
Texte intégral:
Disponible
Indice:
IMSEAR (Asie du Sud-Est)
Sujet Principal:
Pipérazines
/
Pyrimidines
/
Thiazoles
/
Protein-tyrosine kinases
/
Humains
/
Leucémie myéloïde chronique BCR-ABL positive
/
Aberrations des chromosomes
/
Protéines de fusion bcr-abl
/
Résultat thérapeutique
/
Survie sans rechute
Type d'étude:
Guide de pratique
/
Étude pronostique
langue:
Anglais
Texte intégral:
Indian J Cancer
Année:
2012
Type:
Article
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS